Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Apremilast
Treatment for Psoriasis
Typical Dosage: 30mg BID
Effectiveness
35%
Safety Score
72%
Clinical Trials
94
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe
Treatment Details
Dosage Range
30mg BID
Time to Effect
12-16 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
120(Treat 120 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$45,000
Monitoring:$300
Side Effect Mgmt:$200
Total Annual:$45,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$180,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$182,000
Cost per Remission
$1,516,667
Prescription Access Economics
Annual Societal Loss per Patient
$5,600
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$300/year
Time Cost
$60/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$45,000/year
Potential OTC Price
$15,000/year
Estimated if OTC available
Early Treatment Benefit
+0.20 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWWARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
3 active trials recruiting for Apremilast in Psoriasis
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
NCT06088199ACTIVE NOT RECRUITINGPHASE3
51 participants
INTERVENTIONAL
Birmingham, United States +29 more
Started: Oct 24, 2023
Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients
NCT06863493NOT YET RECRUITINGPHASE2, PHASE3
125 participants
INTERVENTIONAL
Started: Jun 1, 2025
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
NCT05565560ACTIVE NOT RECRUITINGPHASE3
17 participants
INTERVENTIONAL
Nagoya, Japan +28 more
Started: Jan 25, 2023
Completed Clinical Trials
17 completed trials for Apremilast in Psoriasis
A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium
NCT03097003COMPLETED
124 participants
OBSERVATIONAL
Bruges, Belgium +21 more
Started: Apr 6, 2017
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
NCT04175613COMPLETEDPHASE3
160 participants
INTERVENTIONAL
Phoenix, United States +49 more
Started: Dec 20, 2019
Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis
NCT00606450COMPLETEDPHASE2
260 participants
INTERVENTIONAL
Edmonton, Canada +30 more
Started: Apr 1, 2006
Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis
NCT03587194COMPLETEDPHASE4
50 participants
INTERVENTIONAL
East Windsor, United States
Started: Jul 23, 2018
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
NCT03701763COMPLETEDPHASE3
245 participants
INTERVENTIONAL
Birmingham, United States +98 more
Started: Dec 19, 2018
Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）
NCT05863273COMPLETED
360 participants
OBSERVATIONAL
Shenyang, China +1 more
Started: May 22, 2023
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
NCT00773734COMPLETEDPHASE2
352 participants
INTERVENTIONAL
Fresno, United States +34 more
Started: Sep 1, 2008
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
NCT02576678COMPLETEDPHASE2
42 participants
INTERVENTIONAL
San Diego, United States +17 more
Started: Oct 13, 2015
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
NCT03757013COMPLETED
453 participants
OBSERVATIONAL
Amiens, France +92 more
Started: Sep 25, 2018
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
NCT03777436COMPLETEDPHASE3
289 participants
INTERVENTIONAL
Birmingham, United States +51 more
Started: Feb 11, 2019
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
NCT00521339COMPLETEDPHASE2
31 participants
INTERVENTIONAL
Boston, United States +3 more
Started: Aug 1, 2007
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
NCT01988103COMPLETEDPHASE2
254 participants
INTERVENTIONAL
Fukuoka, Japan +55 more
Started: Jul 9, 2013
A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life
NCT03774875COMPLETEDPHASE4
277 participants
INTERVENTIONAL
Bordeaux, France +71 more
Started: Mar 28, 2019
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
NCT03123471COMPLETEDPHASE3
303 participants
INTERVENTIONAL
Rogers, United States +44 more
Started: May 16, 2017
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
NCT00604682COMPLETEDPHASE2
19 participants
INTERVENTIONAL
New Brunswick, United States +2 more
Started: Jan 1, 2005
A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice
NCT04031027COMPLETED
184 participants
OBSERVATIONAL
Ancona, Italy +15 more
Started: Jul 22, 2019
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
NCT03721172COMPLETEDPHASE3
595 participants
INTERVENTIONAL
Birmingham, United States +63 more
Started: Mar 11, 2019
Showing 20 of 101 total trials